首页> 美国卫生研究院文献>Scientific Reports >Pharmacokinetics Biodistribution and Anti-Angiogenesis Efficacy of Diamino Propane Tetraiodothyroacetic Acid-conjugated Biodegradable Polymeric Nanoparticle
【2h】

Pharmacokinetics Biodistribution and Anti-Angiogenesis Efficacy of Diamino Propane Tetraiodothyroacetic Acid-conjugated Biodegradable Polymeric Nanoparticle

机译:二氨基丙烷四碘代甲状腺乙酸共轭可生物降解聚合物纳米粒子的药代动力学生物分布和抗血管生成作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The anti-angiogenic agent, diamino propane tetraiodothyroacetic acid (DAT), is a thyro-integrin (integrin αvβ3) antagonist anticancer agent that works via genetic and nongenetic actions. Tetraiodothyroacetic acid (tetrac) and DAT as thyroid hormone derivatives influence gene expression after they transport across cellular membranes. To restrict the action of DAT to the integrin αvβ3 receptors on the cell surface, we used DAT-conjugated PLGA nanoparticles (NDAT) in an active targeting mode to bind to these receptors. Preparation and characterization of NDAT is described, and both in vitro and in vivo experiments were done to compare DAT to NDAT. Intracellular uptake and distribution of DAT and NDAT in U87 glioblastoma cells were evaluated using confocal microscopy and showed that DAT reached the nucleus, but NDAT was restricted from the nucleus. Pharmacokinetic studies using LC-MS/MS analysis in male C57BL/6 mice showed that administration of NDAT improved the area under the drug concentration curve AUC(0–48 h) by 4-fold at a dose of 3 mg/kg when compared with DAT, and Cmax of NDAT (4363 ng/mL) was 8-fold greater than that of DAT (548 ng/mL). Biodistribution studies in the mice showed that the concentrations of NDAT were higher than DAT/Cremophor EL micelles in heart, lung, liver, spleen, and kidney. In another mouse model using female NCr nude homozygous mice with U87 xenografts, tumor growth was significantly decreased at doses of 1 and 3 mg/kg of NDAT. In the chick chorioallantoic membrane (CAM) assay used to measure angiogenesis, DAT (500 ng/CAM) resulted in 48% inhibition of angiogenesis levels. In comparison, NDAT at low dose (50 ng/CAM) showed 45% inhibition of angiogenesis levels. Our investigation of NDAT bridges the study of polymeric nanoparticles and anti-angiogenic agents and offers new insight for the rational design of anti-angiogenic agents.
机译:抗血管生成剂二氨基丙烷四碘胸苷乙酸(DAT)是一种通过基因和非基因作用起作用的甲状腺整联蛋白(integrinαvβ3)拮抗剂抗癌剂。作为甲状腺激素衍生物的四碘甲状腺乙酸(​​tetrac)和DAT在跨细胞膜转运后会影响基因表达。为了将DAT的作用限制在细胞表面上的整联蛋白αvβ3受体上,我们使用了DAT偶联的PLGA纳米颗粒(NDAT)以主动靶向模式与这些受体结合。描述了NDAT的制备和表征,并进行了体外和体内实验以比较DAT和NDAT。使用共聚焦显微镜评估U87胶质母细胞瘤细胞中DAT和NDAT的细胞内摄取和分布,并显示DAT到达细胞核,但NDAT受细胞核限制。使用LC-MS / MS分析在雄性C57BL / 6小鼠中进行的药代动力学研究表明,与3μg/ kg剂量相比,给予NDAT可使药物浓度曲线AUC(0–48 h)下的面积增加4倍。 DAT和NDAT(4363ng / mL)的Cmax比DAT(548μng/ mL)高8倍。小鼠的生物分布研究表明,在心脏,肺,肝脏,脾脏和肾脏中,NDAT的浓度高于DAT / Cremophor EL胶束。在另一只使用雌性NCr裸纯合小鼠和U87异种移植物的小鼠模型中,剂量为1和3μmg/ kg NDAT,肿瘤的生长明显降低。在用于测量血管生成的雏鸡绒膜尿囊膜(CAM)分析中,DAT(500μng/ CAM)导致血管生成水平受到48%的抑制。相比之下,低剂量(50μng/ CAM)的NDAT表现出45%的血管生成水平抑制作用。我们对NDAT的研究为聚合物纳米颗粒和抗血管生成剂的研究架起了桥梁,并为抗血管生成剂的合理设计提供了新的见识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号